Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
GlaxoSmithKline ( (GB:GSK) ) just unveiled an update.
GSK plc continued executing its share buyback programme on 14 April 2026, repurchasing 325,000 ordinary shares at a volume-weighted average price of 2,176.46p through BNP Paribas SA. The shares, which will be held in treasury, form part of a broader capital-management strategy that has seen 18,871,521 shares retired since mid-February and leaves 6.38% of voting rights now held in treasury, affecting the denominator used by investors to calculate disclosure thresholds.
Following this latest transaction, GSK holds 258,762,615 shares in treasury and has 4,057,428,154 ordinary shares in issue, establishing the updated total of voting rights at the same figure. The move underscores the company’s ongoing efforts to return capital to shareholders and manage its equity base, with implications for per-share metrics and regulatory reporting under the UK Financial Conduct Authority’s transparency rules.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £22.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GSK Stock
According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.
The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.
To see Spark’s full report on GSK stock, click here.
More about GlaxoSmithKline
GSK plc is a global biopharmaceutical company focused on developing and manufacturing prescription medicines, vaccines and consumer healthcare products. The group targets major therapeutic areas such as infectious diseases, respiratory conditions and oncology, with a broad presence across developed and emerging markets.
Average Trading Volume: 9,653,972
Technical Sentiment Signal: Buy
Current Market Cap: £86.7B
Find detailed analytics on GSK stock on TipRanks’ Stock Analysis page.